Literature DB >> 12433682

Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL.

Wendy A G Stams1, Monique L den Boer, H Berna Beverloo, Jules P P Meijerink, Rolinda L Stigter, Elisabeth R van Wering, Gritta E Janka-Schaub, Rosalyn Slater, Rob Pieters.   

Abstract

The (12;21) translocation resulting in TEL/AML1 gene fusion is present in about 25% of childhood precursor B-lineage acute lymphoblastic leukemia (ALL) and is associated with a good prognosis and a high cellular sensitivity to L-asparaginase (L-Asp). ALL cells are thought to be sensitive to L-Asp due to lower asparagine synthetase (AS) levels. Resistance to L-Asp may be caused by an elevated cellular level of AS or by the ability of resistant cells to rapidly induce the expression of the AS gene on L-Asp exposure. AS may be a target regulated by t(12;21). We studied the relationship between t(12;21) and the mRNA level of AS to investigate a possible mechanism underlying L-Asp sensitivity. Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis surprisingly revealed that 30 patients positive for t(12;21) expressed 5-fold more AS mRNA compared with 17 patients negative for t(12;21) (P =.008) and 11 samples from healthy controls (P =.016). The mRNA levels of AS between t(12;21)(-) ALL and healthy controls did not differ. No difference was found between ALL patients positive or negative for t(12;21) in the capacity to up-regulate AS after in vitro L-Asp exposure, excluding a defective capacity for t(12;21) cells in up-regulating AS on L-Asp exposure. Moreover, no correlation was observed between AS mRNA expression and sensitivity to L-Asp. We conclude that the sensitivity of t(12;21)(+) childhood ALL to L-Asp is not associated with the expression level of the AS gene. Furthermore, we contradict the general thought that leukemic cells specifically lack AS compared with normal bone marrow and blood cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433682     DOI: 10.1182/blood-2002-08-2446

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.

Authors:  S-H Chen; W Yang; Y Fan; G Stocco; K R Crews; J J Yang; S W Paugh; C-H Pui; W E Evans; M V Relling
Journal:  Leukemia       Date:  2010-11-12       Impact factor: 11.528

Review 3.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

4.  A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.

Authors:  Naina Patel; Shekhar Krishnan; Marc N Offman; Marcin Krol; Catherine X Moss; Carly Leighton; Frederik W van Delft; Mark Holland; Jizhong Liu; Seema Alexander; Clare Dempsey; Hany Ariffin; Monika Essink; Tim O B Eden; Colin Watts; Paul A Bates; Vaskar Saha
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

Review 5.  Understanding the Intersections between Metabolism and Cancer Biology.

Authors:  Matthew G Vander Heiden; Ralph J DeBerardinis
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

6.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.

Authors:  Amy Holleman; Monique L den Boer; Renée X de Menezes; Meyling H Cheok; Cheng Cheng; Karin M Kazemier; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; William E Evans; Rob Pieters
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

7.  A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Authors:  Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

8.  Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.

Authors:  Ehsan A Ehsanipour; Xia Sheng; James W Behan; Xingchao Wang; Anna Butturini; Vassilios I Avramis; Steven D Mittelman
Journal:  Cancer Res       Date:  2013-04-12       Impact factor: 12.701

9.  Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.

Authors:  Philip L Lorenzi; Jenny Llamas; Michele Gunsior; Laurent Ozbun; William C Reinhold; Sudhir Varma; Helen Ji; Hijoo Kim; Amy A Hutchinson; Elise C Kohn; Paul K Goldsmith; Michael J Birrer; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  Functional analysis of a novel DNA polymorphism of a tandem repeated sequence in the asparagine synthetase gene in acute lymphoblastic leukemia cells.

Authors:  Tadayuki Akagi; Dong Yin; Norihiko Kawamata; Claus R Bartram; Wolf-K Hofmann; Jee Hoon Song; Carl W Miller; Monique L den Boer; H Phillip Koeffler
Journal:  Leuk Res       Date:  2008-12-02       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.